KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Part of paid clinical trials in Los Angeles, California.

Sponsor
Kumquat Biosciences Inc.
Study ID
NCT07406633
Phase
PHASE2
Status
Recruiting

Conditions

  • GIST
  • GIST - Gastrointestinal Stromal Tumor
  • GIST Metastatic Cancer
  • Gastro Intestinal Stromal Tumour
  • Gastrointestinal Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • KQB198 — DRUG
    Oral KQB198
  • Imatinib (Gleevec) — DRUG
    Oral Imatinib

Study Details

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: KQB198 in Combination with Imatinib

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 30 months ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033-
Mayo Clinic - JacksonvilleJacksonvilleFlorida32224-
Moffitt Cancer CenterTampaFlorida33612-
University of Michigan HospitalsAnn ArborMichigan48109-
Mayo Clinic - RochesterRochesterMinnesota55905-
Cleveland ClinicClevelandOhio44195-
UT MD Anderson Cancer CenterHoustonTexas77030-
Fred Hutchinson Cancer CenterSeattleWashington98195-

Find similar trials in Los Angeles, CA

Related Studies